Sensitive and specific detection of circulating tumor cells promotes precision medicine for cancer

Huang, Qinqin; Chen, Xingxiang; Jiang, Wei; Jin, Shuiling; Wang, Xingyu; Liu, Wei; Guo, Shishang; Jiang, Guo Liang; Zhao, Xing‐Zhong

doi:10.20517/2394-4722.2018.94

Cited by 6 publications

(6 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…siCD44 and siITGB3). Number of cells: (15,15,12) for siCTL(B1, CD44)-siITGB1-siCD44 ; (11,12) for siCTL(A5)-siITGA5 ; (11,13) for siCTL(B3)-siITGB3. P-values for each case with respect to its control: (siITGB1: 0.005, siCD44: 5 ⇥ 10 5 , siITGA5: 0.001, siITGB3: 0.05).…”

Section: Adhesion Modelingmentioning

confidence: 99%

Deciphering circulating tumor cells binding in a microfluidic system thanks to a parameterized mathematical model

Ciavolella,

Granet,

Goetz

et al. 2023

Preprint

View full text Add to dashboard Cite

Metastatic spread is a crucial process in which some questions remain unanswered. In this work, we focus on tumor cells circulating in the bloodstream, so-called Circulating Tumor Cells (CTCs). We aim to characterize their trajectories under the influence of hemodynamic forces and adhesion forces resulting from interaction with an endothelial layer using in vitro measurements performed with a microfluidic device. This essential step in tumor spread precedes intravascular arrest and metastatic extravasation. Our strategy is based on a differential equation model - a Poiseuille model for the fluid velocity and an ODE system for the cell adhesion model - and allows us to separate the two phenomena underlying cell motion: transport of the cell through the fluid and adhesion to the endothelial layer. A robust calibration procedure enables us to characterize the dynamics. Our strategy reveals the expected role of the glycoprotein CD44 compared to the integrin ITGB1 in the deceleration of CTCs and quantifies the strong impact of the fluid velocity in the protein binding.

show abstract

Section: Adhesion Modelingmentioning

confidence: 99%

Deciphering circulating tumor cells binding in a microfluidic system thanks to a parameterized mathematical model

Ciavolella,

Granet,

Goetz

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…CTCs counts ranging from 0 up to 4 CTCs in 7.5 mL of blood are indicative of a favorable prognosis, while a cut-off of 5 CTCs in 7.5 mL of whole blood indicates an unfavorable prognosis for both metastatic breast and metastatic prostate cancers, while in the case of metastatic colon cancer a cut-off of 3 CTCs suggests poor prognosis [ 9 - 11 ] . Currently, CTC enumeration through CellSearch® for these three metastatic cancer settings is the only clinical application for CTCs [ 13 ] .…”

Section: Circulating Tumor Cells: Weakness In Raritymentioning

confidence: 99%

In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity

Renzi¹,

Marco²,

Meo³

et al. 2022

CDR

View full text Add to dashboard Cite

Since taking part as leading actors in driving the metastatic process, circulating tumor cells (CTCs) have displayed a wide range of potential applications in the cancer-related research field. Besides their well-proved prognostic value, the role of CTCs in both predictive and diagnostics terms might be extremely informative about cancer properties and therefore highly helpful in the clinical decision-making process. Unfortunately, CTCs are scarcely released in the blood circulation and their counts vary a lot among different types of cancer, therefore CTC detection and consequent characterization are still highly challenging. In this context, in vitro CTC cultures could potentially offer a great opportunity to expand the number of tumor cells isolated at different stages of the disease and thus simplify the analysis of their biological and molecular features, allowing a deeper comprehension of the nature of neoplastic diseases. The aim of this review is to highlight the main attempts to establish in vitro CTC cultures from patients harboring different tumor types in order to highlight how powerful this practice could be, especially in optimizing the therapeutic strategies available in clinical practice and potentially preventing or contrasting the development of treatment resistance.

show abstract

“…Currently, a few diagnostics markers are available, namely circulating cancer cells in the blood CTCs (circulating tumor cells), epigenetic markers such as ADAMTS1 (disintegrin A and metalloproteinases with thrombospondin motifs), tumor markers such as CA19-9 (cancer antigen 19-9), autoantibodies such as anti-MUC1 (mucin 1), ENOA1/2 (alfa-enolase), or against RAD1 (RAD1 checkpoint DNA exonuclease) for the early diagnosis of the disease and assessment of prognosis, and microRNAs such as miR-196a, miR-221, and miR-155 [ 39 , 41 ]. The most commonly used method is the detection of CTCs, and it is characterized with a high sensitivity and specificity [ 42 ]. Another method accepted by the FDA (Food and Drug Administration) is the detection of CA19-9 antibodies, but this has a low sensitivity (70%) and specificity (87%) [ 43 ].…”

Section: Introductionmentioning

confidence: 99%

The Link between Diabetes, Pancreatic Tumors, and miRNAs—New Players for Diagnosis and Therapy?

Kozłowska

Śliwińska

2023

IJMS

View full text Add to dashboard Cite

Despite significant progress in medicine, pancreatic cancer is one of the most tardily diagnosed cancer and is consequently associated with a poor prognosis and a low survival rate. The asymptomatic clinical picture and the lack of relevant diagnostic markers for the early stages of pancreatic cancer are believed to be the major constraints behind an accurate diagnosis of this disease. Furthermore, underlying mechanisms of pancreatic cancer development are still poorly recognized. It is well accepted that diabetes increases the risk of pancreatic cancer development, however the precise mechanisms are weakly investigated. Recent studies are focused on microRNAs as a causative factor of pancreatic cancer. This review aims to provide an overview of the current knowledge of pancreatic cancer and diabetes-associated microRNAs, and their potential in diagnosis and therapy. miR-96, miR-124, miR-21, and miR-10a were identified as promising biomarkers for early pancreatic cancer prediction. miR-26a, miR-101, and miR-200b carry therapeutic potential, as they not only regulate significant biological pathways, including the TGF-β and PI3K/AKT, but their re-expression contributes to the improvement of the prognosis by reducing invasiveness or chemoresistance. In diabetes, there are also changes in the expression of microRNAs, such as in miR-145, miR-29c, and miR-143. These microRNAs are involved, among others, in insulin signaling, including IRS-1 and AKT (miR-145), glucose homeostasis (hsa-miR-21), and glucose reuptake and gluconeogenesis (miR-29c). Although, changes in the expression of the same microRNAs are observed in both pancreatic cancer and diabetes, they exert different molecular effects. For example, miR-181a is upregulated in both pancreatic cancer and diabetes mellitus, but in diabetes it contributes to insulin resistance, whereas in pancreatic cancer it promotes tumor cell migration, respectively. To conclude, dysregulated microRNAs in diabetes affect crucial cellular processes that are involved in pancreatic cancer development and progression.

show abstract

Sensitive and specific detection of circulating tumor cells promotes precision medicine for cancer

Cited by 6 publications

References 93 publications

Deciphering circulating tumor cells binding in a microfluidic system thanks to a parameterized mathematical model

Deciphering circulating tumor cells binding in a microfluidic system thanks to a parameterized mathematical model

In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity

The Link between Diabetes, Pancreatic Tumors, and miRNAs—New Players for Diagnosis and Therapy?

Contact Info

Product

Resources

About